Research
Hormonal
Tirzepatide 1-year persistence rates were 64.0% in 2023 and 64.8% in 1H 2024.
The high persistence rates for tirzepatide indicate its potential effectiveness and acceptance among patients for weight management.
StrongSupportsmedium confidence
For tirzepatide, 1-year persistence rates in 2023 and 1H 2024 (the only years the product was available) were 64.0% and 64.8%, respectively.
Why this rating
Based on the cohort study design with a large sample size.
Source
Trends in 1-year persistence and adherence among initiators of high-potency, weight loss–indicated glucagon-like peptide 1 receptor agonists
Landon Marshall et al. · Journal of Managed Care & Specialty Pharmacy · 2026
DOI 10.18553/jmcp.2026.32.3.281
cohort · n=62650Cited 1×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →